ClinicalTrials.gg
CompletedNCT02547714Updated Sep 11, 2017Results posted

Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A

A Phase 4 interventional study of Secukinumab (AIN457) in Plaque Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 11 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
34
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.

Enrollment
43rd of 54
34 · median 124
Started
2015
with 6 others
Phase 4
17 of 54
4 open now
Registered
28th of 54
by date
Lead sponsor
37 of 54
Novartis Pharmaceuticals

Among the 54 studies testing secukinumab in Psoriasis, this one is the 43rd largest by enrollment, is one of 7 that started in 2015, is one of 17 in phase 4, and was the 28th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing secukinumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study was to assess the efficacy and safety of secukinumab at Week 16 based on psoriasis area and severity index (PASI) 75 in subjects who had inadequate response to cyclosporine A.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • cyclosporine A
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Plaque psoriasis diagnosed for at least 6 months before baseline - Treated with cyclosporine A for at least 12 weeks prior to baseline
  • Currently treated with cyclosporine A at baseline for psoriasis but is a primary or secondary inadequate response as defined at baseline by:

    • PASI score of 10 or greater and
    • IGA mod 2011 score of 2 or greater (based on a scale of 0 to 4)

Exclusion criteria

Exclusion Criteria:

  • Forms of psoriasis other than plaque (e.g., pustular, erythrodermic and guttate psoriasis). -Drug-induced psoriasis (i.e., new onset or current exacerbation from beta-blockers, calcium channel blockers or lithium).
  • Patients who have to discontinue cyclosporine A treatment due to side effects like renal impairment (serum creatinine exceeding 176.8 μmol/L [2.0 mg/dL]) and hypertension at screening.

Other protocol-defined inclusion/exclusion criteria may apply

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Secukinumab (AIN457) 300 mg

    Participants received secukinumab 300 mg subcutaneously (s.c.) (two 150 mg injections) on Day 1 and at Weeks 1, 2, 3, 4, 8 and 12.

    Drug: Secukinumab (AIN457)

Interventions

  • Secukinumab was supplied as 150 mg doses, provided in 1 mL prefilled syringes.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved ≥ 75% Psoriasis Area and Severity Index (PASI 75)

    PASI is a combined assessment of a lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for a final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area \* area score weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4). PASI 75 was defined as participants achieving \>= 75% improvement from baseline.

    Time frame: Week 16

Secondary outcomes

  1. Mean Percent Change From Baseline in PASI Score

    PASI is a combined assessment of a lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for a final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area \* area score weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4). A negative change from baseline indicates improvement.

    Time frame: Week 4

  2. Percentage of Participants Achieving PASI 50 or PASI 75

    PASI is a combined assessment of a lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for a final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area \* area score weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4). PASI 50 and PASI 75 were defined as participants achieving \>= 50% or \>= 75% improvement from baseline, respectively.

    Time frame: Week 4

  3. Percentage of Participants Achieving PASI 90 and Investigator's Global Assessment (IGA) of 0 or 1 Response

    PASI is a combined assessment of a lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for a final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area \* area score weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4). PASI 90 was defined as participants achieving \>= 90% improvement from baseline. The IGA scale is static, i.e. it referred exclusively to the participant's disease at the time of assessment and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.

    Time frame: Week 16

  4. Mean Percent Change From Baseline in Dermatology Life Quality Index (DLQI) Score

    The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral warts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.

    Time frame: Week 16

  5. Percentage of Participants Achieving DLQI 0 or 1

    The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral warts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.

    Time frame: Week 16

07

Results

Posted Jun 27, 2017

Participant flow

Participant flow — Overall Study
MilestoneSecukinumab (AIN457) 300 mg
Started34
Completed34
Not completed0

Outcome measures

PrimaryPercentage of Participants Who Achieved ≥ 75% Psoriasis Area and Severity Index (PASI 75)

PASI is a combined assessment of a lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for a final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area \* area score weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4). PASI 75 was defined as participants achieving \>= 75% improvement from baseline.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved ≥ 75% Psoriasis Area and Severity Index (PASI 75)
Percentage of participantsSecukinumab (AIN457) 300 mg
Percentage of Participants Who Achieved ≥ 75% Psoriasis Area and Severity Index (PASI 75)82.4
SecondaryMean Percent Change From Baseline in PASI Score

PASI is a combined assessment of a lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for a final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area \* area score weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4). A negative change from baseline indicates improvement.

Time frame:
Week 4
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in PASI Score
Percent changeSecukinumab (AIN457) 300 mg
Mean Percent Change From Baseline in PASI Score-65.64 ± 37.200
SecondaryPercentage of Participants Achieving PASI 50 or PASI 75

PASI is a combined assessment of a lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for a final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area \* area score weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4). PASI 50 and PASI 75 were defined as participants achieving \>= 50% or \>= 75% improvement from baseline, respectively.

Time frame:
Week 4
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving PASI 50 or PASI 75
Percentage of participantsSecukinumab (AIN457) 300 mg
PASI 5076.5
PASI 7544.1
SecondaryPercentage of Participants Achieving PASI 90 and Investigator's Global Assessment (IGA) of 0 or 1 Response

PASI is a combined assessment of a lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for a final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area \* area score weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4). PASI 90 was defined as participants achieving \>= 90% improvement from baseline. The IGA scale is static, i.e. it referred exclusively to the participant's disease at the time of assessment and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving PASI 90 and Investigator's Global Assessment (IGA) of 0 or 1 Response
Percentage of participantsSecukinumab (AIN457) 300 mg
PASI 9064.7
IGA 0/170.6
SecondaryMean Percent Change From Baseline in Dermatology Life Quality Index (DLQI) Score

The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral warts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.

Time frame:
Week 16
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in Dermatology Life Quality Index (DLQI) Score
Percent changeSecukinumab (AIN457) 300 mg
Mean Percent Change From Baseline in Dermatology Life Quality Index (DLQI) Score-63.07 ± 59.192
SecondaryPercentage of Participants Achieving DLQI 0 or 1

The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral warts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving DLQI 0 or 1
Percentage of participantsSecukinumab (AIN457) 300 mg
Percentage of Participants Achieving DLQI 0 or 176.5

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Entire Period - Secukinumab (AIN457)—0/34 (0%)24/34 (70.6%)
Induction Period - Secukinumab (AIN457)—0/34 (0%)10/34 (29.4%)
Most frequent other events
Showing 10 of 28
Most frequent other events
EventEntire Period - Secukinumab (AIN457)Induction Period - Secukinumab (AIN457)
NasopharyngitisInfections and infestations7/344/34
Dermatitis contactSkin and subcutaneous tissue disorders2/341/34
RashSkin and subcutaneous tissue disorders2/340/34
HypertensionVascular disorders2/341/34
Conjunctivitis allergicEye disorders1/340/34
Dry eyeEye disorders1/340/34
DiarrhoeaGastrointestinal disorders1/340/34
Gastric polypsGastrointestinal disorders1/340/34
GastritisGastrointestinal disorders1/340/34
Gastrooesophageal reflux diseaseGastrointestinal disorders1/340/34

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Secukinumab (AIN457) 300 mg
Mean51.5 ± 12.08
Sex: Female, Male
Sex: Female, Male(Participants)Secukinumab (AIN457) 300 mg
Female10
Male24
08

Study locations

11 sites
  • Novartis Investigative Site
    Nagoya city, Aichi 467-8602, Japan
  • Novartis Investigative Site
    Fukuoka-city, Fukuoka 814-0180, Japan
  • Novartis Investigative Site
    Isehara-city, Kanagawa 259-1193, Japan
  • Novartis Investigative Site
    Osaka-city, Osaka 550-0012, Japan
  • Novartis Investigative Site
    Shimotsuke-city, Tochigi 329-0498, Japan
  • Novartis Investigative Site
    Chiyoda-ku, Tokyo 102-8798, Japan
  • Novartis Investigative Site
    Itabashi-ku, Tokyo 173-8606, Japan
  • Novartis Investigative Site
    Itabashi-ku, Tokyo 173-8610, Japan
  • Novartis Investigative Site
    Minato-ku, Tokyo 105-8471, Japan
  • Novartis Investigative Site
    Shinagawa-ku, Tokyo 141 8625, Japan
  • Novartis Investigative Site
    Shinjuku-Ku, Tokyo 169-0073, Japan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in May 2016, 10 months.

Results were first posted in Jun 2017, 1 year 1 month after primary completion.

Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 10 months is below that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2015
First posted
Sep 11, 2015
StartActual
Jun 16, 2015
Primary completionActual
May 2, 2016
CompletionActual
May 2, 2016
Results first posted
Jun 27, 2017
Last update
Sep 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02547714
Responsible party
Sponsor
First posted
Sep 11, 2015
Start date
Jun 16, 2015
Primary completion
May 2, 2016
Completion
May 2, 2016
Results posted
Jun 27, 2017
Last update
Sep 11, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion